Efficacy

As seen in Table 1, the composite endpoint was reduced significantly in argatro-ban-treated patients versus controls with HIT (25.6% vs. 38.8%, p = 0.014). In HITTS, the composite endpoint occurred in 43.8% of argatroban-treated patients compared with 56.5% of controls (p = 0.13). Significant between-group differences by time-to-event analysis of the composite endpoint favored argatroban treatment in HIT (p = 0.010, hazard ratio = 0.60; 95% CI, 0.40-0.89) (Fig. 5a) and HITTS (p = 0.014, hazard ratio = 0.57; 95% CI, 0.36-0.90) (Fig. 5b).

TABLE 1 Comparisons of Argatroban-Treated Patients with Historical Controls in ARG-911

TABLE 1 Comparisons of Argatroban-Treated Patients with Historical Controls in ARG-911

0 0

Post a comment